You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for FERRIC MALTOL


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for FERRIC MALTOL

Vendor Vendor Homepage Vendor Sku API Url
NovoSeek ⤷  Start Trial 169535 ⤷  Start Trial
AAA Chemistry ⤷  Start Trial AR-1J2564 ⤷  Start Trial
ABI Chem ⤷  Start Trial AC1L53XL ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for FERRIC MALTOL

Last updated: February 20, 2026

FERRIC MALTOL is a chelated iron compound used to treat iron deficiency anemia. Its production involves sourcing raw materials and manufacturing processes that ensure purity, stability, and compliance with pharmaceutical standards. Overview of API sourcing reveals primary producers, regional manufacturing hubs, and supply chain considerations.

Primary API Manufacturers for Ferric Maltol

Major API suppliers for ferric maltol are limited, reflecting its specialized production process limited to select pharmaceutical companies. The key players include:

Manufacturer Location Capacity Certification Notes
Vifor Pharma AG Switzerland High GDP, GMP Original developer and primary supplier
Sandoz (Novartis) Switzerland / Other Moderate GMP Licensed manufacturer for global markets
Bachem AG Switzerland / Germany Small GMP Contract manufacturing for clinical supplies
Other Contract Manufacturers Asia / Europe Varies GMP Emerging suppliers, smaller scale, often under license agreements

Regional and Supply Chain Dynamics

Europe: Dominant in API production, with Switzerland leading via Vifor Pharma, holding intellectual property rights and manufacturing capacity.

Asia: Growing number of contract manufacturers offering API synthesis under licensing agreements, often at lower costs but with variable quality assurance standards, making due diligence essential.

United States: No significant domestic manufacturing of ferric maltol API reported. Import reliance is high for finished API.

Manufacturing and Quality Standards

Manufacturers adhere to Good Manufacturing Practices (GMP) to assure API purity, stability, and batch-to-batch consistency. Certifications, including Good Distribution Practice (GDP), are critical for sourcing, especially for regulated markets.

Standard Description
GMP (Good Manufacturing Practice) Ensures quality, safety, and efficacy of APIs through validated production processes
GDP (Good Distribution Practice) Ensures safe storage and transportation of APIs to prevent contamination or degradation

Supply Chain Considerations

  • Intellectual property rights: Vifor Pharma retains primary rights; licensing agreements enable others.
  • Regulatory approval: API sources must align with the regulatory agencies' standards (FDA, EMA, TGA).
  • Quality assurance: Certifications, audits, and batch testing are mandatory before procurement.
  • Pricing: Cost varies with volume, origin, and certification; Asia offers lower-cost options with tiered quality assurance.

Market Trends and Outlook

  • Increased demand for ferric maltol for anemia treatments is driven by its favorable safety profile.
  • Supply chain risks include geopolitical factors, manufacturing capacity constraints, and sourcing compliance.
  • Emerging contract manufacturers in Asia are expanding capacity but need to meet Western standards.

Summary

Existing API sources for ferric maltol are concentrated in Switzerland with Vifor Pharma as the primary producer. Asia hosts emerging manufacturing capabilities, often under licensing agreements but with variable quality controls. The supply chain relies heavily on GMP-certified facilities aligned with global regulatory standards. Buyers should prioritize certified suppliers with proven quality control processes to mitigate risks.

Key Takeaways

  • Vifor Pharma is the main supplier of ferric maltol API, holding primary manufacturing rights.
  • Asia supplies small-to-moderate volumes via contract manufacturing but requires rigorous quality verification.
  • API sourcing depends heavily on compliance with GMP and GDP standards.
  • Regional manufacturing hubs affect cost, quality, and supply chain resilience.
  • Regulatory and quality certifications are essential for minimizing risk in procurement.

FAQs

1. Are there generic manufacturers for ferric maltol API?
There are no widely recognized generic manufacturers; most production is controlled or licensed by Vifor Pharma or its licensees.

2. What are the quality standards required for ferric maltol API?
Manufacturers must comply with GMP, with certifications verified through audits and batch testing.

3. Which regions dominate API production for ferric maltol?
Switzerland and Europe lead, with emerging capabilities in Asia.

4. How does licensing impact API sourcing?
Licensing agreements restrict direct access to production by non-licensed entities but open opportunities through authorized contract manufacturers.

5. What are the main risks in sourcing ferric maltol API?
Risks include supply chain disruptions, quality variance from emerging suppliers, and regulatory non-compliance.


[1] Vifor Pharma AG. (2022). Company overview and product information. Retrieved from https://www.viforpharma.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.